Elsevier

Current Opinion in Virology

Volume 18, June 2016, Pages 50-56
Current Opinion in Virology

Current status and prospects of HIV treatment

https://doi.org/10.1016/j.coviro.2016.03.004Get rights and content
Under a Creative Commons license
open access

Highlights

  • With no available cure, treatment of HIV infection requires life-long therapy.

  • A combination of three drugs is the current standard for chronic HIV therapy.

  • Multiple single-tablet 3-drug combination regimens are available.

  • Long-term success of HIV therapy requires both efficacy and safety/tolerability.

  • Novel drug classes are in clinical development for patients with drug resistance.

Current antiviral treatments can reduce HIV-associated morbidity, prolong survival, and prevent HIV transmission. Combination antiretroviral therapy (cART) containing preferably three active drugs from two or more classes is required for durable virologic suppression. Regimen selection is based on virologic efficacy, potential for adverse effects, pill burden and dosing frequency, drug–drug interaction potential, resistance test results, comorbid conditions, social status, and cost. With prolonged virologic suppression, improved clinical outcomes, and longer survival, patients will be exposed to antiretroviral agents for decades. Therefore, maximizing the safety and tolerability of cART is a high priority. Emergence of resistance and/or lack of tolerability in individual patients require availability of a range of treatment options. Development of new drugs is focused on improving safety (e.g. tenofovir alafenamide) and/or resistance profile (e.g. doravirine) within the existing drug classes, combination therapies with improved adherence (e.g. single-tablet regimens), novel mechanisms of action (e.g. attachment inhibitors, maturation inhibitors, broadly neutralizing antibodies), and treatment simplification with infrequent dosing (e.g. long-acting injectables). In parallel with cART innovations, research and development efforts focused on agents that target persistent HIV reservoirs may lead to prolonged drug-free remission and HIV cure.

Cited by (0)